-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

Benzinga·07/28/2026 15:00:42
Listen to the news
Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $42 to $44.